PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 مناظر
• 07/08/23
0
0
ایمبیڈ
administrator
سبسکرائبرز
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
مزید دکھائیں
فیس بک کے تبصرے
SORT BY-
سرفہرست تبصرے
-
تازہ ترین تبصرے